Read our Annual Report 2018
MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.
First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!
We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.
Find out more about our therapeutic pipeline.